• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Icagen to Webcast Upcoming Sickle Cell Disease Day Investor and Analyst Meeting

Posted on: Tuesday, 28 March 2006, 18:00 CST

Icagen, Inc. (NASDAQ: ICGN) today announced plans to webcast its Sickle Cell Disease Day Investor and Analyst Meeting scheduled for Friday, March 31, 2006 in New York City.

During this meeting, Icagen will provide a review of the clinical and therapeutic aspects of sickle cell disease. The meeting will include presentations by two leading sickle cell disease physicians and by Icagen senior executives.

The presentation webcast and accompanying slides will be available on Icagen's website at www.icagen.com. The live webcast will begin at 8:30 a.m. ET and will conclude at 1:00 p.m. An archived version of the webcast presentation will also be available on Icagen's website for at least two weeks following the meeting.

About Icagen

Icagen, Inc. is a biopharmaceutical company based in Research Triangle Park, North Carolina, focused on the discovery, development and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets. Utilizing its proprietary know-how and integrated scientific and drug development capabilities, Icagen has identified multiple drug candidates that modulate ion channels. The Company's four most advanced programs are:

-- ICA-17043 for sickle cell disease, for which the Company is conducting a pivotal Phase III clinical trial;

-- a compound for atrial fibrillation, which is being developed by the Company's collaborator BMS and for which an initial Phase I safety study has been completed;

-- lead compounds for epilepsy and neuropathic pain, for which the Company is conducting preclinical studies; and

-- lead compounds for dementia, including Alzheimer's disease, for which the Company's collaborator Astellas is conducting preclinical studies, and lead compounds for attention deficit/hyperactivity disorder ("ADHD"), which were derived from the collaboration and for which the Company is conducting preclinical studies.

Icagen is also conducting ongoing drug discovery programs focused on new therapeutics for pain disorders, inflammatory disorders and glaucoma.

Forward Looking Statements

This press release contains forward-looking statements that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "believes,""anticipates,""plans,""expects,""intends," and similar expressions are intended to identify forward-looking statements. Important factors that could cause actual results to differ materially from the expectations described in these forward-looking statements are set forth under the caption "Risk Factors" in the Company's most recent Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 15, 2006. These risk factors include risks as to whether the Company's products will advance in the clinical trials process, the timing of such clinical trials, whether the results obtained in preliminary studies will be indicative of results obtained in clinical trials, whether the clinical trial results will warrant continued product development, whether and when, if at all, the Company's products, including ICA-17043, will receive approval from the U.S. Food and Drug Administration or equivalent regulatory agencies, and for which indications, and if such products receive approval, whether they will be successfully marketed; the Company's history of net losses and how long the Company will be able to operate on its existing capital resources; and the Company's dependence on third parties, including manufacturers, suppliers and collaborators. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Source: Business Wire

More News in this Category